Premium
O4‐11‐05: A PROOF OF CONCEPT PHASE II STUDY REPURPOSING ATOMOXETINE FOR NEUROPROTECTION IN MILD COGNITIVE IMPAIRMENT: EVIDENCE FOR TARGET ENGAGEMENT, REGULATION OF CSF BIOMARKERS, AND DISEASE‐MODIFYING POTENTIAL
Author(s) -
Levey Allan I.,
Lah James J.,
Hu William T.,
Wingo Thomas S.,
Hales Chadwick M.,
Manzanares Cecelia,
Tansey Malu G.,
Goldstein David S.,
Zhao Liping,
Galasko Douglas R.,
Edland Steven D.,
Hanfelt John,
Weinshenker David
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.4804
Subject(s) - neuroprotection , placebo , medicine , neurodegeneration , oncology , pharmacology , disease , psychology , pathology , alternative medicine
Karolinska Institutet Center for Alzheimer Research, Stockholm, Sweden; Center for Alzheimer Research and Treatment, Brigham and Womens Hospital, Harvard Medical School, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA; University of Southern California, San Diego, CA, USA; Alzheimer’s Association, Chicago, IL, USA; Institute of Clinical Medicine, Kuopio, Finland; University of Eastern Finland, Kuopio, Finland; University of California, Davis, Sacramento, CA, USA. Contact e-mail: ldbaker@wakehealth.edu